Sinopia Biosciences
Sinopia Biosciences is a biotechnology company focused on data-driven drug discovery (D4). They leverage high-throughput multi-omics data, AI/machine learning, and network analyses, combined with disease models, to discover novel medicines. Their proprietary LEADS® platform integrates high-throughput screening, multi-omics data, AI/machine learning, and network analyses to rapidly identify novel targets and mechanisms. Sinopia is actively developing first-in-class programs in areas like neurology, oncology, and genetic diseases, with a lead program for Parkinson's disease. The company has secured significant grant funding from various NIH institutes and The Michael J. Fox Foundation, validating their approach and platform.
Sinopia Biosciences
Sinopia Biosciences is a biotechnology company focused on data-driven drug discovery (D4). They leverage high-throughput multi-omics data, AI/machine learning, and network analyses, combined with disease models, to discover novel medicines. Their proprietary LEADS® platform integrates high-throughput screening, multi-omics data, AI/machine learning, and network analyses to rapidly identify novel targets and mechanisms. Sinopia is actively developing first-in-class programs in areas like neurology, oncology, and genetic diseases, with a lead program for Parkinson's disease. The company has secured significant grant funding from various NIH institutes and The Michael J. Fox Foundation, validating their approach and platform.